研究人员开发阿尔茨海默氏病药物RI-AG03,针对陶蛋白质,在实验室研究中显示出有希望的结果。 Researchers develop Alzheimer's drug RI-AG03 targeting Tau protein, showing promising results in lab studies.
来自兰开斯特大学和其他机构的研究人员研制了一种有前途的阿尔茨海默氏病药物RI-AG03,针对与该疾病有关的陶牛蛋白的两个关键领域。 Researchers from Lancaster University and other institutions have developed a promising Alzheimer's drug, RI-AG03, which targets two key areas of the Tau protein associated with the disease. 在实验室和果研究中,该药物有效地阻止了Tau蛋白的积累,这可能导致神经退行性疾病的治疗得到改善. In laboratory and fruit fly studies, the drug effectively prevented Tau protein build-up, potentially leading to improved treatments for neurodegenerative diseases. 今后在推进临床试验之前,将先进行鼠类试验。 Future testing will involve rodents before advancing to clinical trials.